Evaluation and comparison of vitamin A supplementation with standard therapies in the treatment of patients with COVID-19.

Background: Incomplete data are often presented for determining the role of vitamin A supplement therapy for improving treatment outcomes in patients with COVID-19. Aims: We compared treatment effects between a group that received vitamin A added to the standard COVID-19 treatment and another group that received the standard drug treatment alone. Methods: Participants in this triple-blind controlled trial comprised 182 COVID-19 outpatients in Saveh City, Markazi Province, Islamic Republic of Iran, in 2020. Patients were randomly divided into experimental (n = 91) and control (n = 91) groups. Patients in the control group received the national standard treatment for COVID-19 (hydroxychloroquine), and those in the intervention group received 25 000 IU/d oral vitamin A for 10 days in addition to the standard treatment recommended by the national protocol. We evaluated the clinical symptoms, paraclinical criteria, and hospitalization status before and after 10 days of interventions. Results: The treatment groups did not differ significantly in clinical and paraclinical symptoms before the intervention. However, clinical symptoms such as fever, body ache, weakness and fatigue, paraclinical symptoms, white blood cell count, and C-reactive protein showed significantly greater decreases in the experimental group 10 days post-intervention compared with the standard treatment alone (P < 0.05). Conclusion: Vitamin A supplementation demonstrated efficacy in improving some clinical and paraclinical symptoms in patients with COVID-19. Future studies should evaluate vitamin A supplementation with a larger sample size and compare different dosages, especially in hospitalized patients.

Reduced Graphene Oxide UWB Array Sensor: High Performance for Brain Tumor Imaging and Detection.

A low cost, with high performance, reduced graphene oxide (RGO) Ultra-wide Band (UWB) array sensor is presented to be applied with a technique of confocal radar-based microwave imaging to recognize a tumor in a human brain. RGO is used to form its patches on a Taconic substrate. The sensor functioned in a range of 1.2 to 10.8 GHz under UWB frequency. The sensor demonstrates high gain of 5.2 to 14.5 dB, with the small size of 90 mm × 45 mm2, which can be easily integrated into microwave imaging systems and allow the best functionality. Moreover, the novel UWB RGO array sensor is established as a detector with a phantom of the human head. The layers' structure represents liquid-imitating tissues that consist of skin, fat, skull, and brain. The sensor will scan nine different points to cover the whole one-sided head phantom to obtain equally distributed reflected signals under two different situations, namely the existence and absence of the tumor. In order to accurately detect the tumor by producing sharper and clearer microwave image, the Matrix Laboratory software is used to improve the microwave imaging algorithm (delay and sum) including summing the imaging algorithm and recording the scattering parameters. The existence of a tumor will produce images with an error that is lower than 2 cm.

Patient-adjusted deep-brain stimulation programming is time saving in dystonia patients.

BACKGROUND: Deep-brain stimulation (DBS) programming for dystonia patients is a complex and time-consuming task. OBJECTIVE: To analyze whether programming a programming paradigm based on patient's self-adjustment is practical, effective and time saving in dystonia. METHODS: We retrospectively compared dystonia rating scales as well as the time necessary to optimize programming and the number of in-hospital visits in all patients (n = 102) operated at our center who used simple mode (SM) or advanced mode (AM) programming; the latter uses groups of different stimulation parameters and allows the patient and their caregiver to change stimulation groups at home, using the patient remote control. RESULTS: Both AM- and SM-allocated patients improved clinically to the same extent after DBS, as assessed by the Burke-Fahn-Marsden (BFM) and the Toronto Western Spasmodic Torticollis (TWSTRS) dystonia rating scales. All subscores improved after DBS without statistically significant differences in improvement between AM and SM (BFM: - 43% vs. - 53%, p = 0.569; TWSTRS: - 63% vs. - 72%, p = 0.781). AM and SM patients reached optimization within a similar median time [5.5 months (95% CI 4.6-6.3) for AM vs. 6.2 months (4.2-7.6) for SM, p = 0.674) but patients on advanced programming needed fewer in-hospital visits to achieve the same improvement [median of 5 visits (95% CI 4-7) for AM vs. 8 visits (7-9) for SM, p = 0.008]. CONCLUSIONS: Advanced DBS programming based on patient's self-adjustment under the supervision of the treating physician is feasible, practical and significantly reduces consultation time in dystonia patients.